Acazicolcept(TD-HY422046) is a research-grade recombinant antibody targetingCD28. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Functional assay, Research in vivo
Isotype
Fusion - [ICOSLG N-terminal fragment (1-122)]2 - IGHG1 Fc (Fragment constant)
Protein A/G purified from cell culture supernatant.
Accession
P10747 & Q9Y6W8
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
ALPN-101, ICOSLvIgD-Fc, 2270247-50-0
Background
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
Caption
Detects CD28 in indirect ELISAs. | SDS-PAGE for Research Grade Acazicolcept
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询